New drug DR-01 tested for alopecia and vitiligo
NCT ID NCT06602232
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 39 times
Summary
This early-stage study tests a new medicine called DR-01 in 81 adults with alopecia areata (patchy hair loss) or vitiligo (white patches on skin). The main goals are to check safety and see if the drug can improve hair regrowth or skin color. Participants are randomly assigned to different doses, and everyone knows which treatment they receive.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dren Investigational Site
Northridge, California, 91344, United States
-
Dren Investigational Site
Miami, Florida, 33155, United States
-
Dren Investigational Site
Evans, Georgia, 30809, United States
-
Dren Investigational Site
Meridian, Idaho, 83642, United States
-
Dren Investigational Site
Indianapolis, Indiana, 46250, United States
-
Dren Investigational Site
West Lafayette, Indiana, 47906, United States
-
Dren Investigational Site
Worcester, Massachusetts, 01605, United States
-
Dren Investigational Site
Troy, Michigan, 48084, United States
-
Dren Investigational Site
Philadelphia, Pennsylvania, 19103, United States
-
Dren Investigational Site
Pittsburgh, Pennsylvania, 15213, United States
-
Dren Investigational Site
Chattanooga, Tennessee, 37421, United States
-
Dren Investigational Site
San Antonio, Texas, 78215, United States
-
Dren Investigational Site
Charlestown, New South Wales, 2290, Australia
-
Dren Investigational Site
Darlinghurst, New South Wales, 2010, Australia
-
Dren Investigational Site
Coorparoo, Queensland, 4151, Australia
-
Dren Investigational Site
South Yarra, Victoria, 3141, Australia
-
Dren Investigational Site
Fremantle, Washington, Australia
-
Dren Investigational Site
Auckland, 0632, New Zealand
-
Dren Investigational Site
Christchurch, 8013, New Zealand
-
Dren Investigational Site
Grafton, 1010, New Zealand
Conditions
Explore the condition pages connected to this study.